Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Pulmonary 2-deoxy-2-[(18)F]-fluoro-d-glucose uptake is low in treated patients with idiopathic pulmonary arterial hypertension.

Ruiter G, Wong YY, Raijmakers P, Huisman MC, Lammertsma AA, Knaapen P, de Man FS, Westerhof N, van der Laarse WJ, Vonk-Noordegraaf A.

Pulm Circ. 2013 Sep;3(3):647-53. doi: 10.1086/674335. Epub 2013 Nov 18.

2.

A weight index for the standardized uptake value in 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography.

Thie JA, Hubner KF, Isidoro FP, Smith GT.

Mol Imaging Biol. 2007 Mar-Apr;9(2):91-8.

PMID:
17205367
3.

Acute hemodynamic effects of nebulized iloprost via the I-neb Adaptive Aerosol Delivery system in pulmonary hypertension.

Richter MJ, Ghofrani HA, Voswinckel R, Seeger W, Schulz R, Reichenberger F, Gall H.

Pulm Circ. 2015 Mar;5(1):162-70. doi: 10.1086/679722.

4.
6.

The Prognostic Value of 18F-FDG Uptake Ratio Between the Right and Left Ventricles in Idiopathic Pulmonary Arterial Hypertension.

Li W, Wang L, Xiong CM, Yang T, Zhang Y, Gu Q, Yang Y, Ni XH, Liu ZH, Fang W, He JG.

Clin Nucl Med. 2015 Nov;40(11):859-63. doi: 10.1097/RLU.0000000000000956.

PMID:
26359560
7.

Assessment of patient selection criteria for quantitative imaging with respiratory-gated positron emission tomography.

Bowen SR, Pierce LA, Alessio AM, Liu C, Wollenweber SD, Stearns CW, Kinahan PE.

J Med Imaging (Bellingham). 2014 Jul;1(2):026001. doi: 10.1117/1.JMI.1.2.026001. Epub 2014 Sep 24.

8.

Shorter survival in familial versus idiopathic pulmonary arterial hypertension is associated with hemodynamic markers of impaired right ventricular function.

Brittain EL, Pugh ME, Wheeler LA, Robbins IM, Loyd JE, Newman JH, Larkin EK, Austin ED, Hemnes AR.

Pulm Circ. 2013 Sep;3(3):589-98. doi: 10.1086/674326. Epub 2013 Dec 3.

9.

Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.

Schmidt H, Brendle C, Schraml C, Martirosian P, Bezrukov I, Hetzel J, Müller M, Sauter A, Claussen CD, Pfannenberg C, Schwenzer NF.

Invest Radiol. 2013 May;48(5):247-55. doi: 10.1097/RLI.0b013e31828d56a1.

PMID:
23519008
10.

Novel positron emission tomography/computed tomography of diffuse parenchymal lung disease combining a labeled somatostatin receptor analogue and 2-deoxy-2[18F]fluoro-D-glucose.

Win T, Screaton NJ, Porter J, Endozo R, Wild D, Kayani I, Dickson J, Shortman RI, Reubi JC, Ell PJ, Groves AM.

Mol Imaging. 2012 Apr;11(2):91-8.

11.

Regional 2-[18F]fluoro-2-deoxy-D-glucose uptake varies in normal lung.

Miyauchi T, Wahl RL.

Eur J Nucl Med. 1996 May;23(5):517-23.

PMID:
8698055
12.

Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues.

Paquet N, Albert A, Foidart J, Hustinx R.

J Nucl Med. 2004 May;45(5):784-8.

13.

(18)FDG PET imaging can quantify increased cellular metabolism in pulmonary arterial hypertension: A proof-of-principle study.

Hagan G, Southwood M, Treacy C, Ross RM, Soon E, Coulson J, Sheares K, Screaton N, Pepke-Zaba J, Morrell NW, Rudd JH.

Pulm Circ. 2011 Oct-Dec;1(4):448-55. doi: 10.4103/2045-8932.93543.

14.

[[Formula: see text]]acetate and PET/CT assessment of muscle activation in rat studies.

Trombella S, García D, Colin DJ, Germain S, Seimbille Y, Ratib O.

Int J Comput Assist Radiol Surg. 2016 May;11(5):733-43. doi: 10.1007/s11548-015-1260-8. Epub 2015 Jul 26.

PMID:
26210940
15.

FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features.

Higashi K, Ueda Y, Ayabe K, Sakurai A, Seki H, Nambu Y, Oguchi M, Shikata H, Taki S, Tonami H, Katsuda S, Yamamoto I.

Nucl Med Commun. 2000 Aug;21(8):707-14.

PMID:
11039452
16.

Fluoro-deoxy-glucose positron emission tomography for evaluation of indeterminate lung nodules: assigning a probability of malignancy may be preferable to binary readings.

Kim SC, Machac J, Krynyckyi BR, Knesaurek K, Krellenstein D, Schultz B, Gribetz A, DePalo L, Teirstein A, Kim CK.

Ann Nucl Med. 2008 Apr;22(3):165-70. doi: 10.1007/s12149-007-0112-1. Epub 2008 May 23. Erratum in: Ann Nucl Med. 2010 Apr;24(3):231. Kim, Suk C [corrected to Kim, Suk Chul].

PMID:
18498030
17.
18.

Anatomical considerations for the development of a new transcatheter aortopulmonary shunt device in patients with severe pulmonary arterial hypertension.

Guo K, Langleben D, Afilalo J, Shimony A, Leask R, Marelli A, Martucci G, Therrien J.

Pulm Circ. 2013 Sep;3(3):639-46. doi: 10.1086/674328. Epub 2013 Nov 18.

19.

11C-Acetate clearance as an index of oxygen consumption of the right myocardium in idiopathic pulmonary arterial hypertension: a validation study using 15O-labeled tracers and PET.

Wong YY, Raijmakers P, van Campen J, van der Laarse WJ, Knaapen P, Lubberink M, Ruiter G, Vonk Noordegraaf A, Lammertsma AA.

J Nucl Med. 2013 Aug;54(8):1258-62. doi: 10.2967/jnumed.112.115915. Epub 2013 Jun 4.

20.

18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trials.

Win T, Lambrou T, Hutton BF, Kayani I, Screaton NJ, Porter JC, Maher TM, Endozo R, Shortman RI, Lukey P, Groves AM.

Eur J Nucl Med Mol Imaging. 2012 Mar;39(3):521-8. doi: 10.1007/s00259-011-1986-7. Epub 2011 Nov 30.

PMID:
22258710
Items per page

Supplemental Content

Write to the Help Desk